Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Rhea-AI Summary

Mirati Therapeutics, Inc. announced the publication of preclinical and initial clinical data for MRTX1719, a PRMT5/MTA inhibitor, in Cancer Discovery. The data demonstrate that MRTX1719 may represent a promising targeted therapy for cancer patients with MTAP deletion, with marked anti-tumor activity observed in preclinical studies. In the Phase 1/2 trial, six confirmed objective responses were observed, and MRTX1719 was well-tolerated with no dose-limiting toxicities observed.

The detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that blocking PRMT5-MTA complex is a rational and differentiated approach to treat cancers harboring MTAP deletion

Partial responses observed in patients with advanced cancer along with a well-tolerated safety profile demonstrate MRTX1719 may represent a potential new therapeutic strategy for the treatment of multiple cancer types that have strong unmet medical need

SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.^® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine (MTA)-cooperative inhibitor evaluated in methylthioadenosine phosphorylase (MTAP) deleted cancers. These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker. The publication can be found here.

In preclinical studies, MRTX1719 was demonstrated to be a potent, selective inhibitor of the PRMT5/MTA complex. This compound exploits the elevated MTA levels present in MTAP-deleted cancers and turns this altered metabolic state into a therapeutic vulnerability to selectively kill MTAP deleted cancer cells while sparing normal cells. Preclinical results showed marked anti-tumor activity of MRTX1719, including regression, across lung, pancreatic, mesothelioma, and other solid tumor models.

As of June 13, 2023, there were 18 patients with solid tumors harboring MTAP deletions in the Phase 1/2 trial of MRTX1719 that were evaluable for clinical response at dose levels of 100mg QD or greater. Initial dose level started at 50mg administered once-daily orally over 21-day cycles followed by 100% dose escalations for subsequent dose levels. Six individual case narratives were selected for inclusion in the Cancer Discovery publication:

• There were six confirmed objective responses observed in the Phase 1 study including one patient who achieved a response which subsequently confirmed post-data cutoff
• MRTX1719 achieved apparent complete PRMT5 inhibition in MTAP deleted tumor cells at a dose of 200 mg QD as evidenced by pretreatment and on-treatment tumor biopsies of the PRMT5 biochemical biomarker symmetric dimethyl arginine (SDMA)
• It was notable that four patients were on therapy for multiple cycles before experiencing an initial objective response, with their tumors continuing to decrease in size over the course of treatment.
• These findings suggest that tumor response may continue to deepen over time indicating the importance of evaluating tumor response kinetics and response rates across a broader patient population with longer follow up.
• MRTX1719 was well-tolerated with no dose limiting toxicities observed at dose levels up to 400mg QD. None of the patients treated with MRTX1719 experienced dose-limiting adverse events associated with first generation PRMT5 inhibitors such as thrombocytopenia, anemia or neutropenia.

"Many cancers with a prevalence of MTAP deletion have few treatment options so it is encouraging to see these initial responses in the clinic. These data, including the favorable safety profile, demonstrate the development of a possible therapeutic approach for a significant population of patients with MTAP-deleted cancers in need of new treatment options," said Jordi Rodon Ahnert, MD, PhD, The University of Texas MD Anderson Cancer Center. "It will be important for next-generation sequencing tests to expand their panel of targets to include for markers of PRMT5 inhibition."

"The targeting strategy of MRTX1719 is differentiated from first generation PRMT5 inhibitors and has so far shown to be well tolerated in this patient population with dire unmet need," said James Christensen, Ph.D., chief scientific officer, Mirati Therapeutics, Inc. "We are pleased that Cancer Discovery recognized the importance and potential impact of this early data from MRTX1719, and we look forward to pursuing continued development of MRTX1719 for the benefit of patients living with cancer."

About MRTX1719 (MTA-cooperative PRMT5 inhibitor)

MRTX1719, discovered at Mirati, is an orally bioavailable, methylthioadenosine (MTA)-cooperative PRMT5 inhibitor that exhibits synthetic lethality in MTAP-deleted cancers. MTAP deletion leads to MTA accumulation in cancer cells and MRTX1719 is designed to selectively bind the PRMT5-MTA complex ultimately inhibiting PRMT5 function in MTAP-deleted cancer cells while sparing healthy non-tumor cells.¹ MTAP deletions occur in around 10% of all cancers², including a high percentage of pancreatic cancer, non-small cell lung cancer, and mesothelioma which are associated with a poor prognosis, representing a significant unmet medical need. The PRMT5-MTA complex creates a novel drug target for the treatment of MTAP-deleted cancers. Targeting this complex involves a new and potentially improved therapeutic approach. MRTX1719 is being evaluated as monotherapy and in combination with other therapeutic options to treat patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

For more information visit Mirati.com/science.

About Mirati Therapeutics, Inc.^®

Mirati Therapeutics, Inc. is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook. 

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^® (adagrasib), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (https://www.sec.gov/). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com

References

1. Smith C.R., Aranda R, Bobinski T.P., Briere D.M., Burns A.C., et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Jan 18. doi: 10.1021/acs.jmedchem.1c01900. Online ahead of print.
2. Han G, Yang G, Hao D, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 Sep 23;12(1):5606. doi: 10.1038/s41467-021-25894-9.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-discovery-publishes-preclinical-and-initial-clinical-data-for-mrtx1719-to-treat-mtap-deleted-cancers-through-novel-approach-to-mta-cooperative-prmt5-inhibition-301897212.html

SOURCE Mirati Therapeutics, Inc.

FAQ

What is the company behind MRTX1719?

Mirati Therapeutics, Inc. is the company behind MRTX1719.

What is the target of MRTX1719?

MRTX1719 is a PRMT5/MTA inhibitor.

What is the potential therapeutic strategy of MRTX1719?

MRTX1719 may represent a potential new therapeutic strategy for the treatment of multiple cancer types that have strong unmet medical need.

What is the biomarker associated with MRTX1719?

MTAP deletion is the biomarker associated with MRTX1719.

What were the preclinical results of MRTX1719?

Preclinical results showed marked anti-tumor activity of MRTX1719, including regression, across lung, pancreatic, mesothelioma, and other solid tumor models.

How many patients were evaluated in the Phase 1/2 trial of MRTX1719?

As of June 13, 2023, there were 18 evaluable patients with solid tumors harboring MTAP deletions in the Phase 1/2 trial of MRTX1719.

How many objective responses were observed in the Phase 1 study?

Six confirmed objective responses were observed in the Phase 1 study.

What dose of MRTX1719 achieved complete PRMT5 inhibition?

MRTX1719 achieved complete PRMT5 inhibition at a dose of 200 mg QD.

Were there any dose-limiting toxicities observed with MRTX1719?

No dose-limiting toxicities were observed with MRTX1719 at dose levels up to 400mg QD.